Atea Pharmaceuticals Financial Statements From 2010 to 2021

AVIR -  USA Stock  

USD 26.37  0.76  2.80%

Atea Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Atea Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Atea Pharmaceuticals financial statements helps investors assess Atea Pharmaceuticals' valuation, profitability, and current liquidity needs.
There are over seventeen available fundamental signals for Atea Pharmaceuticals, which can be analyzed over time and compared to other ratios. Please make sure to validate Atea Pharmaceuticals' prevailing fundamental performance against the performance between 2010 and 2021 to make sure the trends are evolving in the right direction.
As of 09/17/2021, Net Income Per Employee is likely to drop to about (345.7 K). In addition to that, Revenue Per Employee is likely to drop to about 1 M.

Search Financial Statements 

 
Refresh
Check Atea Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Atea Pharmaceuticals main balance sheet or income statement drivers, such as Direct Expenses of 1.4 M, Gross Profit of 43.5 M or Operating Expenses of 47.6 M, as well as many exotic indicators such as Long Term Debt to Equity of 0.0077, PPandE Turnover of 42.93 or Receivables Turnover of 13.11. Atea Pharmaceuticals financial statements analysis is a perfect complement when working with Atea Pharmaceuticals Valuation or Volatility modules. It can also supplement various Atea Pharmaceuticals Technical models. Please continue to the analysis of Atea Pharmaceuticals Correlation against competitors.

Atea Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets931.8 M863.6 M177.6 M
Increasing
Slightly volatile
Cash and Equivalents917.2 M850.1 M175 M
Increasing
Slightly volatile
Deferred Revenue269.6 M271.2 M296.2 M
Decreasing
Slightly volatile
Property Plant and Equipment Net45.6 K48 K53.2 K
Decreasing
Slightly volatile
Trade and Non Trade Receivables5.2 M5.2 M5.7 M
Decreasing
Slightly volatile
Trade and Non Trade Payables61.6 K60 K349 K
Decreasing
Slightly volatile
Total Liabilities340.8 M315.8 M56.4 M
Increasing
Slightly volatile
Shareholders Equity591 M547.8 M63.7 M
Increasing
Slightly volatile
Current Assets931.6 M863.5 M177.4 M
Increasing
Slightly volatile
Assets Non Current149.1 K155 K161.2 K
Decreasing
Slightly volatile
Current Liabilities340.7 M315.8 M56.2 M
Increasing
Slightly volatile
Liabilities Non Current36.9 K36 K125 K
Decreasing
Slightly volatile
Shareholders Equity USD591 M547.8 M63.7 M
Increasing
Slightly volatile
Cash and Equivalents USD917.2 M850.1 M175 M
Increasing
Slightly volatile
Accounts Payable134.9 K131.4 K1.4 M
Decreasing
Slightly volatile
Receivables919.1 K895.5 K4.2 M
Decreasing
Slightly volatile

Atea Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues43.5 M43.8 M47.8 M
Decreasing
Slightly volatile
Selling General and Administrative Expense23.3 M21.6 M6.2 M
Increasing
Slightly volatile
Research and Development Expense30.6 M38 M11.6 M
Increasing
Slightly volatile
Operating Expenses47.6 M59.7 M17.3 M
Increasing
Slightly volatile
Weighted Average Shares19.4 M21.6 M11.8 M
Increasing
Slightly volatile
Weighted Average Shares Diluted19.4 M21.6 M11.8 M
Increasing
Slightly volatile
Revenues USD43.5 M43.8 M47.8 M
Decreasing
Slightly volatile
Gross Profit43.5 M43.8 M47.8 M
Decreasing
Slightly volatile
Direct Expenses1.4 M1.3 M7.5 M
Decreasing
Slightly volatile

Atea Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow from Financing483.7 M611.5 M156.2 M
Increasing
Slightly volatile
Issuance Purchase of Equity Shares394.1 M365.3 M89.8 M
Increasing
Slightly volatile
Net Cash Flow from Operations320.2 M296.7 M44.4 M
Increasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents893.9 M828.5 M157.1 M
Increasing
Slightly volatile
Share Based CompensationM7.5 M1.7 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion20.2 K19 K17.4 K
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Return on Average Equity(0.0452)(0.044)0.2651
Decreasing
Slightly volatile
Return on Invested Capital0.07390.0726.863
Decreasing
Slightly volatile
Gross Margin0.890.90.9829
Decreasing
Slightly volatile
Asset Turnover0.09840.0990.1081
Decreasing
Slightly volatile
Sales per Share2.022.032.2138
Decreasing
Slightly volatile
Price to Sales Ratio16.616.718.2333
Decreasing
Slightly volatile
Price to Book Value5.645.676.1931
Decreasing
Slightly volatile
Debt to Equity Ratio0.620.5770.0561
Increasing
Slightly volatile
Current Ratio2.812.73415.9979
Decreasing
Slightly volatile
Free Cash Flow per Share14.8313.7411.6829
Increasing
Slightly volatile
Book Value per Share27.3725.371.2845
Increasing
Slightly volatile
Tangible Assets Book Value per Share43.1639.9979.7157
Increasing
Slightly volatile
Total Assets Per Share2.772.632.3679
Decreasing
Very volatile
Cash Flow Per Share(0.44)(0.41)(0.2751)
Decreasing
Slightly volatile
Receivables Turnover13.1116.5810.1407
Increasing
Slightly volatile
PPandE Turnover42.9349.336.5871
Increasing
Slightly volatile
Cash and Equivalents Turnover0.240.230.3508
Decreasing
Slightly volatile
Accounts Payable Turnover51.948.128.418
Increasing
Slightly volatile
Accrued Expenses Turnover4.124.015.1711
Decreasing
Slightly volatile
Long Term Debt to Equity0.00770.00620.0083
Decreasing
Slightly volatile
Quick Ratio19.3317.9111.2926
Increasing
Slightly volatile
Net Current Assets as percentage of Total Assets10310888.0125
Increasing
Slightly volatile
Revenue to Assets0.260.170.2506
Decreasing
Slightly volatile

Atea Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Capitalization3.1 B3.1 B3.4 B
Decreasing
Slightly volatile
Enterprise ValueBB3.3 B
Decreasing
Slightly volatile
Average Equity268.8 M249.1 M7.4 M
Increasing
Slightly volatile
Average Assets369.5 M442.9 M91.4 M
Increasing
Slightly volatile
Tangible Asset Value931.8 M863.6 M177.6 M
Increasing
Slightly volatile
Free Cash Flow320.1 M296.7 M44.4 M
Increasing
Slightly volatile
Working Capital590.9 M547.7 M121.2 M
Increasing
Slightly volatile
Revenue Per EmployeeMM869.2 K
Increasing
Stable
Net Income Per Employee(345.7 K)(320.4 K)(505.7 K)
Decreasing
Very volatile

Atea Pharmaceuticals Fundamental Market Drivers

Short Percent Of Float5.66%
Forward Price Earnings2.19
Shares Short Prior Month2.24M
Average Daily Volume Last 10 Day1.43M
Average Daily Volume In Three Month1.39M
Date Short Interest15th of April 2021
Fifty Day Average28.59
Two Hundred Day Average36.88

Atea Pharmaceuticals Upcoming Events

Upcoming Quarterly Report9th of December 2021
Next Earnings Report29th of March 2022
Next Fiscal Quarter End30th of September 2021
Next Fiscal Year End29th of March 2022
Last Quarter Report30th of June 2021
Last Earning Announcement30th of September 2020

About Atea Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Atea Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Atea Pharmaceuticals investors use historical funamental indicators, such as Atea Pharmaceuticals's revenue or net income, to determine how well the company is positioned to perform in the future. Although Atea Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Atea Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Atea Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Atea Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Atea Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Deferred Revenue271.2 M269.6 M
Revenues43.8 M43.5 M
Revenue to Assets 0.17  0.26 
Revenue Per EmployeeMM
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts. Atea Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Atea Pharmaceuticals without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Bollinger Bands Now

   

Bollinger Bands

Use Bollinger Bands indicator to analyze target price for a given investing horizon
All  Next Launch Module

Pair Trading with Atea Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Atea Pharmaceuticals Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Atea Pharmaceuticals and Equillium. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Please continue to the analysis of Atea Pharmaceuticals Correlation against competitors. Note that the Atea Pharmaceuticals information on this page should be used as a complementary analysis to other Atea Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Complementary Tools for Atea Pharmaceuticals Stock analysis

When running Atea Pharmaceuticals price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
The market value of Atea Pharmaceuticals is measured differently than its book value, which is the value of Atea Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Atea Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Atea Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea Pharmaceuticals' market value can be influenced by many factors that don't directly affect Atea Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Atea Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.